acid associated with scrapie and possibly the Creutzfeldt-Jakob infectious agents (Kimberlin, 1986) .
The concept of prion infections has been extended to include a group of six rare diseases (Griffin, 1985 , Prusiner et al. 1987 . Three of these diseases occur in animals viz: scrapie, transmissible mink encephalopathy, and chronic wasting disease of deer and elk. Another three diseases occur in man, viz. kuru, Creutzfeldt-Jakob disease and Gerstmann-Straussler syndrome. All six diseases affect the central nervous system, have prolonged incubation periods, are inevitably fatal and are characterized by spongiform change in the brain.
The mode of natural transmission of Creutzfeldt-Jakob disease is unclear. With an incidence of 1 per million ) the disease could scarcely be perpetuated solely by transmission from overt cases. It is, however, possible that the agent is widespread but only rarely pathogenic (Matthews, 1986) . Some clusters of cases have been recorded, but it is not clear how the disease could be transmitted by social contact (Will & Matthews 1982) . A 6-15% familial incidence has been suggested, but doubt has been cast upon these figures through the inclusion of unproven cases (Matthews, 1986) .
Although the origins of the infection in sporadic cases of Creutzfeldt-Jakob disease remain obscure, different routes of experimental transmission of this disease and more especially of scrapie have been extensively investigated. In addition to intracerebral injection, both scrapie and Creutzfeldt-Jakob disease can be transmitted by oral routes and by peripheral injections (Kimberlin, 1986) . Intramuscular injection of the scrapie agent is followed by invasion of the central nervous system from lymphoreticular sites of agent replication. In one scrapie model, spread of the agent occurs along autonomic nerves to the thoracic spinal cord and thence to other parts of the central nervous system (Kimberlin, 1986) . Other studies suggest that the scrapie agent spreads in neurons. There is a close relationship between the presence of replicating scrapie agent and the vacuolated spongiform change in the cerebral cortex (Kimberlin, 1986) .
A number of cases of suspected iatrogenic transmission of Creutzfeldt-Jakob disease were recorded before 1985 (Will & Matthews, 1982) . In one case, a 55 year-old woman died from the disease 18 months after receiving a corneal transplant from a 55 year-old man who was later found to have died from Creutzfeldt-Jakob disease (Duffy et al. 1974) . Two further cases of intracerebral transmission of the disease were reported by Bernoulli et al. (1977) . Transmission in these cases apparently occurred when intracerebral electrodes, previously used in the investigation of a patient with Creutzfeldt-Jakob disease, were temporarily inserted into the brains of two epileptic patients. Although the electrodes had been sterilized by conventional means, this proved to be ineffective for the elimination of the infectious agent. A number of other reports have appeared in which transmission of Creutzfeldt-Jakob disease has been suspected, as in the case of a 28 year-old woman who developed Creutzfeldt-Jakob disease following a neurosurgical operation which included the grafting of commercially prepared dura mater (MMWR, 1987) In early 1985 the distribution of human growth hormone for replacement therapy of growth hormone deficient children was halted by authorities in the United States and in Britain following reports that patients had died of Creutzfeldt-Jakob disease following the administration of human growth hormone. The British case (Powell-Jackson et al. 1985; Weller et al. 1986 ) was a young woman, born in 1962, who at the age of 2 years had a neurosurgical operation for the removal of craniopharyngioma. She subsequently received human growth hormone extracted from post mortem human pituitary glands for a period of 4 years between 1972 and 1976 . In March 1984 , at the age of 22 years, she exhibited clumsiness and unsteadiness while walking. By July of the same year she had developed a mild paraparesis and a left extensor plantar response. No abnormal investigations were noted at this time but during the next few months her behaviour became increasingly childish, demanding and disinhibited. She then developed a slurring dysarthria, disordered eye movements and showed titubation and severe ataxia of the limbs and trunk. There was general intellectual deterioration although no myoclonic movements were observed. A diagnosis of Creutzfeldt-Jakob disease was made despite the absence of myoclonic movements. The patient continued to deteriorate and by December 1984 she was mute and unresponsive; she died in February 1985. The diagnosis of Creutzfeldt-Jakob disease was confirmed by the presence of spongiform change detected histologically in layers 2 and 3 throughout the frontal cortex and in the insula of both cerebral hemispheres. There was neuronal loss with proliferation of reactive astrocytes, particularly in layersS and 6 of the frontal cortex. Spongiform change and gliosis were also present in the putamen, globus pallidus, caudate nucleus and thalamus. Pronounced cerebellar cortical atrophy was observed with loss of granule cells but with relative preservation of Purkinje cells. No spongiform change was seen in the cerebellum but there was extensive gliosis (Weller et al. 1986 ).
The two cases of Creutzfeldt-Jakob disease in the United States, which had originally precipitated the ban on cadaver-pituitary derived human growth hormone administration, were both in their twenties and neither had had intracranial surgery. One patient was a man aged 23 who died 18 months after the onset of clinical signs . A diagnosis of Creutzfeldt-Jakob disease was made from the histological finding of spongiform change in the brain and by the isolation of scrapie-associated fibrils and their constituent protein PrP 27-30 from post mortem brain tissue. The case of Koch et al. (1985) was a 20 year-old man who had received human growth hormone preparations between 1966-1980. He developed signs of Creutzfeldt-Jakob disease in May 1984 and died 6 months later. At post mortem he showed the characteristic spongiform change of CreutzfeldtJakob disease throughout the cerebral cortex, basal ganglia and molecular layer of the cerebellar cortex but with little gliosis or neuronal loss. A further case of Creutzfeldt-Jakob disease in the United States occurred in a 32 year-old man who received growth hormone preparations between 1963 and 1969 (Tintner et al. 1986 ). Clinically, this patient was rather atypical as he exhibited little dementia but gross cerebellar signs. The disease was confirmed by pathology.
There is convincing argument in favour of cadaver-derived pituitary human growth hormone being the source of infection in the three American and one British patients treated with human growth hormone. Of the 3000 reported cases of Creutzfeldt-Jakob disease, only nine were under the age of 30 years . There are now 10000 people in the USA and 2000 in Britain who have received human growth hormone treatment and all are under 40 years of age Preece, 1986) . The probability of three cases of Creutzfeldt-Jakob disease occurring by chance in the American group of patients has been calculated as 1:10 12 . It has proved difficult to predict how many more cases of the disease will occur in the future, but it is hoped that the purification steps used since 1980 in the preparation of human growth hormone from cadaver pituitaries (Taylor et al. 1985) will have eliminated the infectious agent.
Since the original four cases were published, there have been unpublished reports of three definite cases of Creutzfeldt-Jakob disease associated with human growth hormone preparations and one suspicious case. Of the three cases that show pathological evidence of Creutzfeldt-Jakob disease, one died at the end of 1986 in New Zealand having received an American batch of growth hormone in the past. Another two deaths occurred in the United States in 1987. One was a male in his midtwenties who presented with dysarthria and ataxia and not the classical clinical picture of Creutzfeldt-Jakob disease. A female patient who had received growth hormone preparation also died from a non-neurological illness and bronchopneumonia but pathological examination of her brain revealed the changes of spongiform encephalopathy compatible with Creutzfeldt-Jakob disease.
The atypical presentation of Cruetzfeldt-Jakob disease and its long incubation period in some of the patients, especially those reported by Powell Jackson et al. (1985) and by Tintner et al. (1986) , may well be due to the peripheral route of infection (Kimberlin, 1986) . It does mean, however, that the clinical awareness of Creutzfeldt-Jakob disease, particularly in this group, needs to be widened.
Apart from the obvious concern regarding the transmission of Creutzfeldt-Jakob disease to patients who have received human growth hormone preparations, there are also the problems raised by withdrawing growth hormone preparations for hormone-deprived children (Preece, 1986) . However, a safe non-immunogenic human pituitary growth hormone with high activity and produced by recombinant DNA techniques should soon be widely available.
Since the first reports of iatrogenic transmission of Creutzfeldt-Jakob disease, precautions for handling tissues and body products from patients with the disease have been instituted (Rosenberg et al. 1986 ). Avoidance of skin contact with infectious materials is recommended and sterilization procedures for tissue and contaminated material include steam autoclaving for one hour at 132 °C and immersion in IN sodium hydroxide for 1 hour at room temperature. Formalin fixation does not destroy the Cruetzfeldt-Jakob disease agent, as transmission occurs following intracerebral injection of formalin-fixed brain material into non-human primates . It should be noted, however, that no medical staff, laboratory staff or autopsy technicians who are most likely to be exposed to the tissues and body products of patients with Creutzfeldt-Jakob disease have contracted the disease (Rosenberg et al. 1986 ).
R. O. WELLER

